Biologics in COPD
Dupilumab and other biologics for COPD with type 2 inflammation.
Key point
Pooled analyses suggest dupilumab and mepolizumab consistently reduce moderate-to-severe exacerbations in eosinophilic or type 2 inflammatory COPD.
From: Number Needed to Treat with Biologics in Type-2 Inflammation COPD: A Systematic Review and Meta-Analysis (COPD, 2026 Dec) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 18, 19, 21, 30, 38.
New guidelines and consensus this year
- The JRS guideline for the management of chronic obstructive pulmonary disease 7th edition 2026Respir Investig2026 Sep
- Update 2025 of the Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPDArch Bronconeumol2025 Dec
All papers from the last 12 months
421 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- The Iron Lung: Ferroptosis and Iron Regulation in Aging and Lung DiseasesPhysiology (Bethesda)2027 Jan 1PMID 42363743Review
- Monitoring symptoms and performance in rehabilitation: Can we detect COPD exacerbation?Pulmonology2026 DecPMID 42841793
- ALPHA-1 antitrypsin genotype, sex, and lung cancer: Clinical and molecular characterisationPulmonology2026 DecPMID 42750455
- Number Needed to Treat with Biologics in Type-2 Inflammation COPD: A Systematic Review and Meta-AnalysisCOPD2026 DecPMID 42405817Meta-analysisSystematic review
- Association Between the Use of Gabapentinoids and Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysisCurr Ther Res Clin Exp2026 DecPMID 42405224Review
- BMI-mediated association between pulmonary function and bone mineral density moderated by age: Integrated Mendelian randomisation and cross-sectional studyPulmonology2026 DecPMID 42227154
- From trials to clinical practice: Effect of Dupilumab on disease stability in severe COPD. A pilot studyPulmonology2026 DecPMID 42187235
- Plasma proteomic biomarkers as mediators for the associations between frailty phenotypes and chronic respiratory diseasesGeroscience2026 DecPMID 41639365
- Neuroimmune circuits in respiratory pathophysiology: decoding molecular crosstalk for precision therapeutic targetingAnn Med2026 DecPMID 41601146Review
- Efficacy and Safety of Mepolizumab in Eosinophilic COPD: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsAnn Pharmacother2026 NovPMID 42035307Meta-analysisSystematic review
More pulmonology trends
All specialties →New treatments for sleep apnoea
Tirzepatide, hypoglossal nerve stimulation and drug therapy for obstructive sleep apnoea.
Key point: Pharmacological therapy is not routine OSA treatment; dual GIP/GLP-1 agonists such as tirzepatide may be considered adjunctively for obese moderate-to-severe OSA.
High-flow nasal oxygen
High-flow nasal oxygen in acute hypoxaemic respiratory failure.
Key point: HFNC is strongly recommended for adults with acute hypoxemic respiratory failure, with close monitoring for escalation, based primarily on reduced need for intubation.
Bronchiectasis
Non-cystic fibrosis bronchiectasis and its newer treatments.
Robotic and navigational bronchoscopy
Robotic and navigation bronchoscopy to biopsy peripheral lung nodules.
Antifibrotics in pulmonary fibrosis
Nintedanib, pirfenidone and newer antifibrotics.
Biologics in severe asthma
Biologic therapies for severe asthma.
Key point: Biologic choice in adult severe asthma can be impacted by quality of life impairment, lung function, exacerbation frequency, oral corticosteroid use, endotype, biomarkers and comorbidities.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
COPD[tiab] AND (dupilumab[tiab] OR mepolizumab[tiab] OR tezepelumab[tiab] OR itepekimab[tiab] OR astegolimab[tiab] OR biologic*[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.